Dyno Therapeutics utilizes artificial intelligence to design novel adeno-associated virus (AAV) vectors for gene therapy, enhancing delivery efficiency for a wide range of human diseases. The company aims to increase patient access to effective treatments while significantly reducing the cost of in vivo gene delivery.
Funding
$111M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current adeno-associated virus (AAV) vectors used in gene therapy often lack the necessary efficiency and specificity for targeted delivery to specific tissues, limiting the potential of gene therapies for a wide range of human diseases. Traditional vector development methods are slow and costly, hindering the advancement of in vivo gene delivery.
Solution
Dyno Therapeutics is developing a platform that uses artificial intelligence (AI) to design novel AAV vectors with improved delivery properties for gene therapy. The platform aims to overcome the limitations of existing AAV vectors by optimizing tissue targeting and delivery efficiency. By leveraging AI, Dyno Therapeutics seeks to create vectors that can reach more patients and address a broader spectrum of diseases, while also reducing the overall cost of in vivo gene delivery.
Target Audience
The primary target audience includes gene therapy developers, pharmaceutical companies, and research institutions seeking to improve the delivery of gene therapies for various diseases.
Features
- AI-driven design of novel AAV vectors for enhanced tissue specificity
- Optimization of AAV vectors for improved delivery efficiency
- High-performance genetic technologies to unlock the potential of next-gen medicine